high blood pressure, diabetes
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patient inclusion criteria: patients aged 18-80 years with hypertension and diabetes mellitus under community-based management; patients with essential hypertension and type 2 diabetes mellitus who were registered for management at their community health services and continued to reside in the study community; patients who had been receiving stable antihypertensive or diabetic medications for 4 weeks or more at the time of entry into the trial and patients who had given informed consent.
Exclusion criteria
Exclusion criteria: Hypertensive patients: 1. those with blood pressure >=200/110 mm Hg (to avoid adverse events); 2. those with postural hypertension (systolic blood pressure rises >=20 mm Hg after the patient stands up) (to avoid adverse events); 3. those with secondary hypertension; 4. those who are taking >=3 types of medications to control blood pressure; 5. those who have existing target-organ damage; 6. those who have comorbidities with end-stage diseases such as tumors; 7. those who have dementia and cognitive impairment; 8. renal disease and hepatic dysfunction; 9. severe valvular heart disease, cardiomyopathy, unstable angina within 6 months, or coronary artery bypass grafting;10)unwilling to perform self-monitoring of blood pressure; 11. pregnant or planning to become pregnant (the treatment of blood pressure monitoring during pregnancy is different from that of the general patient); 12. participating in other trials. Patients with diabetes mellitus: 1. pregnant women; 2. patients with severe physical (dependence on others for mobility) or mental (active psychosis, major depression, communication disorders, etc.) illnesses, terminal illnesses, or other conditions that impede adherence (inability to care for themselves, alcohol dependence, or drug addiction, etc.); 3. hemoglobinopathies related to HbA1c; 4. a history of stroke or invasive revascularization; anticonvulsant therapy; 5. patients with type 1 diabetes or pancreatic insufficiency; and 6. participants in other trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| systolic blood pressure;diastolic blood pressure;pulse pressure difference;Fasting Plasma Glucose (FPG); | — |
Secondary
| Measure | Time frame |
|---|---|
| Hypertension Patient Awareness;Level of self-management behaviors;Level of self-efficacy; | — |
Countries
China
Contacts
Shandong University